The Derma Co: Building a Brand on Active Ingredients
Industry & Competitive Context
The Derma Co belongs to Honasa Consumer Limited, which launched Mamaearth in 2016, then added five brands (The Derma Co., Aqualogica, Ayuga, BBlunt and Dr. Sheth’s) in a “House of Brands” architecture. In its red herring prospectus (RHP), Honasa described Mamaearth as India’s largest digital-first beauty and personal care brand by FY23 revenue from operations. The company listed on the stock exchanges in November 2023.
In skincare, Honasa cited Euromonitor International (Passport, July 2024) as ranking The Derma Co among India’s top 20 skincare brands and as the largest active-ingredient skincare brand. Media coverage of the 2024 revenue milestone also noted that the brand competes with both local and global brands in the active-ingredient segment.
Competition extends to claims. Honasa’s draft prospectus disclosed that Uprising Science sent a notice alleging that The Derma Co published inaccurate, misleading and defamatory statements about its products on social media.
In sunscreen, a category central to the brand’s later growth, Honasa said the acquisition of Cosmogenesis laboratories would strengthen its R&D and add categories such as sunscreens. Trade coverage in 2026 also shows athlete-led sunscreen advertising by several brands, not only The Derma Co.

Brand Situation Prior to Launch
Honasa’s first brand, Mamaearth, was built on a natural and toxin-free promise. The CEO attributed Honasa’s skincare ranking to a commitment to natural, toxin-free products and consumer trust. The Derma Co launched in 2020, after Mamaearth’s success. Per Honasa’s own press release, it launched in January 2020 as a dermatologist-designed, science-backed brand built on active-ingredient products.
At the group level, Honasa reported FY23 operating revenue of about INR 1,493 crore, up 58% from INR 943 crore in FY22. No verified public information is available on The Derma Co’s standalone revenue, market share or awareness at launch, or for FY21 to FY23.
Analytical reading. The documented facts show a company with one scaled brand on a “natural” axis launching a second on an “efficacy and science” axis.
Strategic Objective
Honasa’s documented statements frame the objective in three layers.
Category leadership. Varun Alagh, Honasa’s co-founder and CEO, said the brand has been a pioneer in bringing active ingredient-led products to Indian skincare since day one.
Scale. In the FY24 annual report, the co-founders said they expected The Derma Co to enter the INR 1,000 crore ARR club in the next three to five years. The same report named distribution expansion and higher brand awareness as growth drivers.
Accessibility. In January 2025, Alagh said the company would strengthen the active-ingredient market through an omnichannel approach so that active-ingredient skincare is easily accessible to consumers everywhere.
Campaign Architecture & Execution
Ingredient-and-concentration product architecture. At the 2021 brand-ambassador launch, the brand’s offer was described as science-backed solutions for concerns such as acne, pigmentation, open pores and dull or dry skin, with ingredients like 20% Vitamin C, 10% Niacinamide, 2% Salicylic Acid and 5% Hyaluronic Acid. The same release said the brand discloses the percentage of its actives on the front of its packaging. By 2025, the range also covered hair concerns such as hair loss.
Celebrity-led launch film. In March 2021, the brand introduced actress Parineeti Chopra as its official face and released its first digital film under a #FilterFree theme.
Premium and international dermatologist partnership. In Q1 FY25, Honasa’s investor materials said The Derma Co and Dr. Vanita Rattan partnered on the “Skin Renew by Dr. V” range, which the company described as India’s first international dermatologist collaboration in the actives category and an entry into the prestige pricing segment. The range was positioned as powered by peptides and retinol and made for Indian skin and weather.
Format and ingredient innovation. Honasa’s Q4 FY24 presentation said the brand introduced format and ingredient-based innovations across categories including serums and sunscreens. One named example was The Derma Co 1% Hyaluronic Long Lasting Sunscreen.
Purpose programme. The company’s press release cites “The Young Scientist” programme, which teaches children in rural and remote areas the science behind climate change.
Suncare ambassador (2026). In March 2026, the brand named tennis player Sania Mirza ambassador for its Suncare category, with the campaign live on digital and social platforms. The partnership began with a campaign film for The Derma Co’s 1% Hyaluronic Sunscreen Aqua Gel.
Analytical reading. Putting the concentration on the pack turns an abstract claim (“active”) into a cue a shopper can check. The documented sequence of mass-priced actives, an international dermatologist collaboration at a higher price tier, and category-specific ambassadors suggests the company layered pricing and credibility within one positioning rather than changing the positioning.
Positioning & Consumer Insight
The brand’s own language is consistent across 2021 to 2025: “dermatologist-designed,” “science-backed,” “active ingredient-based,” and concern-specific. Honasa describes its portfolio as built on a customer insights-led innovation strategy, and the company attributed the 2024 milestone to an on-trend, data-based innovation strategy. honasaoutlookbusiness
No verified public information is available on the consumer research, surveys or data behind the positioning, or on the specific insight the company used.
Analytical reading. The Derma Co and Mamaearth sit on different claim axes (efficacy versus natural safety) under one corporate roof. Honasa’s Q2 FY27 disclosures show Mamaearth maintaining high-teens growth while The Derma Co continued to report profitable growth.
Media & Channel Strategy
Documented channel evolution.
As of January 2025, the brand was available on its own website, leading e-commerce marketplaces and select modern trade outlets.
That month it opened its first exclusive brand outlet at Airia Mall, Gurugram, with a dedicated experiential centre, beauty advisors who explain active ingredients, and a skin analysis tool.
By Q2 FY27, The Derma Co had expanded to more than 65,000 outlets.
The company framed the retail move as a response to demand, saying it had seen strong demand from its existing offline channels across the country.
Company-wide context (not brand-specific). The FY24 annual report said offline channels rose to nearly 35% of Honasa’s net sales in FY24, from 9% in the year ended March 2020.
Media spend. Honasa’s advertising spend rose 16.7% year on year to INR 241 crore in Q1 FY27. That figure covers the whole group.
Business & Brand Outcomes
Date | Documented outcome | Source type |
Apr 2024 | ARR of INR 500 crore, reached under 48 months after launch, per the CEO | Exchange filing; business press |
FY24 | More than 1 crore units sold | Business press |
FY24 | Break-even in all quarters (per investor presentation) | Investor presentation |
Jan 2025 | Delivered to 17.5 million Indian households in the prior year; top-20 skincare brand and largest active-ingredient skincare brand (Euromonitor) | Press release filed with exchanges |
Q1 FY27 | INR 1,000 crore NSV ARR; “teens” EBITDA margin; face cleansers above INR 200 crore ARR | Company results; business press |
Q2 FY27 | Continued profitable growth; 65,000+ outlets | Company results |
The sources for these figures are as follows.
April 2024 milestone. Alagh announced that the brand reached an ARR of INR 500 crore, less than 48 months after launch, and the brand sold over 1 crore units in the last financial year.
FY24 profitability. Honasa’s Q4 FY24 presentation recorded that the brand achieved break-even in all quarters of FY24.
Reach. The January 2025 press release stated that the brand delivered products to 17.5 million Indian households over the past year.
Q1 FY27 milestone. The company reported that The Derma Co crossed INR 1,000 crore in NSV ARR and entered the “teens EBITDA club”. It also said face cleansers alone surpassed INR 200 crore ARR. A trade report on the same results said brand searches rose 34% year on year; that figure is trade-reported, and the underlying source was not verified.
Q2 FY27. The company said The Derma Co maintained its profitable growth trajectory, and new products such as body washes contributed to growth.
Reading the numbers carefully. One analyst-style commentary noted that a INR 1,000 crore annualised figure does not necessarily mean the brand booked exactly that much reported revenue in a financial year. The company’s own target of three to five years from the FY24 report was stated in the annual report published in 2024. The milestone was announced with Q1 FY27 results in August 2026, ahead of the earliest end of that window.
Strategic Implications
This section is analytical interpretation of the documented facts above.
Specificity can be an architecture, not just a message. Named ingredients, disclosed concentrations and concern-specific products gave the brand a repeatable innovation template. The Q4 FY24 and Q1 FY25 launches (hyaluronic sunscreen, peptide serum, peptide and retinol range) follow that template.
Credibility was extended across price tiers. The documented move into a prestige-priced range through an international dermatologist partnership shows the positioning being stretched upward rather than diluted.
A digital-first brand needed an education layer offline. The company’s own description of its first store emphasises advisors and skin analysis to explain actives.
Portfolio logic. Two brands now above INR 1,000 crore ARR, per company statements, support the house-of-brands thesis. That evidence is company-reported.
Open risks visible in the record. These are claims-substantiation disputes (the Uprising Science notice), the dependence of the headline metric on an annualised run-rate, and the fact that competitors also use athlete-led sunscreen marketing.
Discussion Questions
Honasa launched The Derma Co on an efficacy axis while Mamaearth stayed on a natural axis. What are the benefits and risks of building two differently positioned brands inside one company, and what evidence would you need to detect cannibalisation?
The brand prints active-ingredient percentages on the front of the pack. Evaluate this as a differentiation tool versus a vulnerability to competitor imitation and to claims disputes.
The brand moved from online and select modern trade to exclusive stores and 65,000+ outlets. Which parts of an ingredient-led proposition survive the shift from a digital to a physical retail environment, and which need to change?
The company reports ARR and NSV ARR rather than audited brand revenue. How should an investor or marketer weigh run-rate milestones, and what additional disclosures would you request?
The brand used a film-led launch in 2021, an international dermatologist partnership in 2024, and a sports-icon ambassador for suncare in 2026. Which of these three credibility signals, in your assessment, is most transferable to another category, and why?



Comments